ClinicalTrials.gg
CompletedNCT01445769Updated Mar 27, 2019Results posted

Alternative Dosing Strategy of Ruxolitinib in Patients With Myelofibrosis

A Phase 2 interventional study of Ruxolitinib in Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis and Post-Essential Thrombocythemia Myelofibrosis, sponsored by Incyte Corporation. Completed at 21 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-03-27.

Sponsored by Incyte Corporation · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
45
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 50 studies testing ruxolitinib in Primary Myelofibrosis — 8 open to participants now, 15 under way, 1 of them phase 3. ruxolitinib · Primary Myelofibrosis.

Enrollment
25th of 50
45 · median 45
Started
2011
with 5 others
Phase 2
19 of 50
3 open now
Registered
10th of 50
by date
Lead sponsor
5 of 50
Incyte Corporation

Among the 50 studies testing ruxolitinib in Primary Myelofibrosis, this one is the 25th largest by enrollment, is one of 6 that started in 2011, is one of 19 in phase 2, and was the 10th registered.

Primary Myelofibrosis

627 studies on the registry are indexed under Primary Myelofibrosis; 125 are open to participants now.

Browse Primary Myelofibrosis studies →

Open to participants now

8 of the 50 studies testing ruxolitinib in Primary Myelofibrosis are open now, in 1 country. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About ruxolitinib

ruxolitinib: first FDA approval 2011 (JAKAFI), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 101 Primary Myelofibrosis studies recruiting now, 83 (82%) set no upper age limit and 13 (13%) stop at 75 or younger; 10 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies testing ruxolitinib in Primary Myelofibrosis, or all of them as a file.
02

Study summary

The purpose of this study was to evaluate the effect of an alternative dosing strategy of ruxolitinib in subjects with primary myelofibrosis (PMF), post-polycythemia vera-myelofibrosis (PPV-MF) and post essential thrombocythemia-myelofibrosis (PET-MF) in order to minimize the development of anemia and thrombocytopenia.

Read the detailed description

This pilot study was designed to explore an alternative dosing approach with the purpose of reducing anemia and thrombocytopenia. Subjects began dosing at 10 mg bid and had the opportunity for dose increases based on assessments of efficacy and overall hematologic status in a defined prior dosing interval. Dose increases were restricted to those patients who did not meet criteria for or have a dose hold over the prior 6 weeks, had a platelet count ≥100 x 10\^9/L at week 12 or ≥150 x 10\^9/L at week 18, and had a self-reported Patient's Global Impression of Change (PGIC) score of 3 (minimally improved) to 7 (very much worse) OR the subject's palpable spleen length below the costal margin had been reduced by less than 40% at that visit relative to Baseline. Dose increases were elective and not required. Subjects were permitted a dose increase of 5 mg BID to 15 mg BID at Week 12 and to a maximum of 20 mg BID at Week 18. There were also protocol-required dose decreases for thrombocytopenia (platelets \<100 x 10\^9/L) or protocol-defined anemia (decline in hemoglobin of at least 2 g/dL to a level \< 8 g/dL, development of transfusion dependence, or a 50% increase in transfusion requirements for transfusion dependent subjects).This approach assumed that beginning at a low dose for initial therapy might have a positive impact on the rate of the initial hemoglobin decline and the nadir by decreasing the level of JAK-mediated inhibition of hematopoiesis. Specific dose modifications were described to minimize excursions of hemoglobin levels into the Grade 3 or Grade 4 range.

03

Conditions studied

  • Primary Myelofibrosis
  • Post-Polycythemia Vera Myelofibrosis
  • Post-Essential Thrombocythemia Myelofibrosis

Browse trials for

Keywords

  • Myelofibrosis
  • Primary Myelofibrosis
  • PMF
  • Post-Polycythemia Vera Myelofibrosis
  • PPV-MF
  • Post-Essential Thrombocythemia Myelofibrosis
  • PET-MF
  • Open label
  • Ruxolitinib
  • 18424
  • Jak inhibitor
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) as confirmed by bone marrow .
  • Must score at least 2 points on the Dynamic International Prognostic Scoring System (DIPSS) scale for prognostic risk factors.
  • Peripheral blast count \< 5% at both Screening and Baseline hematology assessments.
  • Must discontinue all drugs used to treat underlying myelofibrosis (MF) disease no later than Day -1 (the day prior to starting ruxolitinib).
  • Must have value ≥ 6.5 g/dL and be willing to receive blood transfusions.
  • count ≥ 100*10\^9/L.
  • Must have a palpable spleen.

Exclusion criteria

Exclusion Criteria:

  • Inadequate liver or bone marrow reserves, end stage renal disease on dialysis, concurrent infections requiring therapy, or unstable cardiac function.
  • Invasive over the previous 5 years (except treated early stage carcinomas of the skin, completely resected intraepithelial carcinoma of the cervix, and completely resected papillary thyroid and follicular thyroid cancers).
  • Splenic irradiation within 6 months prior to receiving the first dose of study medication.
  • less than 6 months.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
45 participants (actual)

Study arms

  • Experimental
    Ruxolitinib

    Participants initially received ruxolitinib 10 mg twice a day (bid) for 24 weeks. Dose increases of 5 mg bid were possible at Weeks 12 and 18 up to a maximum dose of 20 mg bid.

    Drug: Ruxolitinib

Interventions

  • Ruxolitinib was provided as 5 mg tablets. Dose increases were only permitted at wks 12 \& 18 for lack of efficacy. Increases were restricted to patients who didn't meet criteria for a dose hold over the prior 6 wks, had a platelet count ≥ 100 x 10\^9/L at wk 12 or ≥ 150 x 10\^9/L at wk 18, and had a self-reported PGIC score of 3 (minimally improved) to 7 (very much worse) OR the subject's palpable spleen length below the costal margin was reduced by less than 40% relative to Baseline. Dose increases were elective and not required. Subjects were permitted a dose increase of 5 mg BID to 15 mg BID at wk 12 and to a maximum of 20 mg BID at wk 18. The protocol required dose decreases for thrombocytopenia (platelets \<100 x 10\^9/L) or protocol-defined anemia (decline in hemoglobin of at least 2 g/dL to a level \< 8 g/dL, development of transfusion dependence, or a 50% increase in transfusion requirements for transfusion dependent subjects).

    Also known as: INCB018424, INC424

06

What researchers measure

Primary outcomes

  1. Mean Percentage Change From Baseline in Spleen Volume at Week 24

    Spleen volume was measured using magnetic resonance imaging (MRI) or computed tomography (CT) scan. The MRIs were read in the central imaging laboratory. Spleen volume was obtained by outlining the circumference of the organ and determining the volume using the technique of least squares. MRI was the preferred method for obtaining spleen volume data. CT scans were performed if the participant was not a candidate for MRI. The CT scans were processed by the same central laboratory used for MRIs. The same method (MRI or CT) was used for all visits for a given participant unless a new contraindication to the use of MRI (eg, pacemaker insertion) occurred.

    Time frame: Baseline to Week 24

  2. Median Percent Change From Baseline in Spleen Volume at Week 24

    Spleen volume was measured using magnetic resonance imaging (MRI) or computed tomography (CT) scan. The MRIs were read in the central imaging laboratory. Spleen volume was obtained by outlining the circumference of the organ and determining the volume using the technique of least squares. MRI was the preferred method for obtaining spleen volume data. CT scans were performed if the participant was not a candidate for MRI. The CT scans were processed by the same central laboratory used for MRIs. The same method (MRI or CT) was used for all visits for a given participant unless a new contraindication to the use of MRI (eg, pacemaker insertion) occurred.

    Time frame: Baseline to Week 24

Secondary outcomes

  1. Mean Percentage Change From Baseline in the Total Symptom Score at Week 24

    Symptoms of myelofibrosis were assessed using a symptom diary, the modified Myelofibrosis Symptom Assessment Form (MFSAF v2.0). Participants were issued a hand-held device to record answers to queries regarding 7 symptoms of myelofibrosis each night from Baseline through Week 24. Symptoms assessed included night sweats, itching, abdominal discomfort, pain under ribs on left, feeling of fullness (early satiety), muscle/bone pain, and inactivity. The daily total symptom score (TSS) was the sum of the first 6 individual symptom scores (each on a scale of 0-10). Inactivity was not included in the total score. The Baseline TSS was the mean of daily total symptom scores from the last 7 consecutive days prior to the first study dose and ranged from 0 to 60. The Week 24 TSS was the mean of the daily total symptom scores from the last 28 consecutive days prior to the Week 24 visit and ranged from 0 to 60. A higher score indicates worse symptoms. A negative change score indicates improvement.

    Time frame: Baseline to Week 24

  2. Median Percent Change From Baseline in the Total Symptom Score at Week 24

    Symptoms of myelofibrosis were assessed using a symptom diary, the modified MFSAF v2.0. Participants were issued a hand-held device to record answers to queries regarding 7 symptoms of myelofibrosis each night from Baseline through Week 24. Symptoms assessed included night sweats, itching, abdominal discomfort, pain under ribs on left, feeling of fullness (early satiety), muscle/bone pain, and inactivity. The daily TSS was the sum of the first 6 individual symptom scores (each on a scale of 0-10). Inactivity was not included in the total score. The Baseline total symptom score was the mean of daily total symptom scores from the last 7 consecutive days prior to the first study dose and ranged from 0 to 60. The Week 24 total symptom score was the mean of the daily total symptom scores from the last 28 consecutive days prior to the Week 24 visit and ranged from 0 to 60. A higher score indicates worse symptoms. A negative change score indicates improvement.

    Time frame: Baseline to Week 24

  3. Percentage of Participants With a ≥ 35% Reduction From Baseline in Spleen Volume at Week 24

    Spleen volume was measured using magnetic resonance imaging (MRI) or computed tomography (CT) scan. The MRIs were read in the central imaging laboratory. Spleen volume was obtained by outlining the circumference of the organ and determining the volume using the technique of least squares. MRI was the preferred method for obtaining spleen volume data. CT scans were performed if the participant was not a candidate for MRI. The CT scans were processed by the same central laboratory used for MRIs. The same method (MRI or CT) was used for all visits for a given participant unless a new contraindication to the use of MRI (eg, pacemaker insertion) occurred.

    Time frame: Baseline to Week 24

  4. Percentage of Participants With a ≥ 10% Reduction From Baseline in Spleen Volume at Week 24

    Spleen volume was measured using magnetic resonance imaging (MRI) or computed tomography (CT) scan. The MRIs were read in the central imaging laboratory. Spleen volume was obtained by outlining the circumference of the organ and determining the volume using the technique of least squares. MRI was the preferred method for obtaining spleen volume data. CT scans were performed if the participant was not a candidate for MRI. The CT scans were processed by the same central laboratory used for MRIs. The same method (MRI or CT) was used for all visits for a given participant unless a new contraindication to the use of MRI (eg, pacemaker insertion) occurred.

    Time frame: Baseline to Week 24

  5. Percentage of Participants With a ≥ 50% Improvement From Baseline in Total Symptom Score at Week 24

    Symptoms of myelofibrosis were assessed using a symptom diary, the modified MFSAF v2.0. Participants were issued a hand-held device to record answers to queries regarding 7 symptoms of myelofibrosis each night from Baseline through Week 24. Symptoms assessed included night sweats, itching, abdominal discomfort, pain under ribs on left, feeling of fullness (early satiety), muscle/bone pain, and inactivity. The daily total symptom score was the sum of the first 6 individual symptom scores (each on a scale of 0-10). Inactivity was not included in the total score. The Baseline total symptom score was the mean of daily total symptom scores from the last 7 consecutive days prior to the first study dose and ranged from 0 to 60. The Week 24 total symptom score was the mean of the daily total symptom scores from the last 28 consecutive days prior to the Week 24 visit and ranged from 0 to 60. A higher score indicates worse symptoms. A negative change score indicates improvement.

    Time frame: Baseline to Week 24

  6. Mean Percentage Change From Baseline in Palpable Spleen Length at Week 24

    Spleen length was assessed by manual palpation. The edge of the spleen was determined by palpation and measured in centimeters, using a soft ruler, from the costal margin to the point of greatest splenic protrusion.

    Time frame: Baseline to Week 24

  7. Median Percent Change From Baseline in Palpable Spleen Length at Week 24

    Spleen length was assessed by manual palpation. The edge of the spleen was determined by palpation and measured in centimeters, using a soft ruler, from the costal margin to the point of greatest splenic protrusion.

    Time frame: Baseline to Week 24

  8. Percentage of Participants With a ≥ 50% Improvement From Baseline in Their Transfusion Status or With New Transfusion Independence Status for Those Participants Who Were Transfusion Dependent at Baseline

    Transfusion dependence at Baseline is defined as subjects who received ≥ 2 units of red blood cell product(s) in the 12 consecutive weeks prior to the date of first dose. Transfusion independence On-Study is defined as subjects who received 0 units of red blood cell products over any 12-week period after starting dosing with ruxolitinib. Improvement in transfusion dependence On-Study is defined as a 50% or greater reduction in the frequency of red blood cell transfusions over any 12-week period after starting dosing with ruxolitinib.

    Time frame: Baseline to Week 24

  9. Percentage of Participants With Clinically Notable Anemia

    Clinically Notable Anemia was a pre-specified safety parameter examined at Weeks 12, 18 and 24 and defined as: 1) New onset Grade 3 or higher anemia in subjects who are transfusion independent at Baseline, 2) New onset transfusion dependence in subjects who are transfusion independent at Baseline, defined as receipt of ≥ 2 units in ≤ a 12-week interval, 3) 50% increase in transfusions compared to Baseline in subjects who are transfusion dependent at Baseline.

    Time frame: Baseline to Weeks 12, 18 and 24

  10. Mean Percentage Change in Abdominal Symptom Scores at Week 24.

    Symptoms of myelofibrosis were assessed using a symptom diary, the modified MFSAF v2.0. Participants were issued a hand-held device to record answers to queries regarding 7 symptoms of myelofibrosis each night from Baseline through Week 24. The abdominal symptom score was the sum of 3 individual symptom scores (abdominal discomfort, pain under ribs on left side, and feeling of fullness \[early satiety\]), each on a scale of 0 to 10. A higher score indicates worse symptoms. A negative change score indicates improvement. The Baseline abdominal symptom score was the mean of daily abdominal symptom scores from the last 7 consecutive days prior to the first study dose and ranged from 0 to 30. The Week 24 abdominal symptom score was the mean of the daily abdominal symptom scores from the last 28 consecutive days prior to the Week 24 visit and ranged from 0 to 30.

    Time frame: Week 24

  11. Median Percentage Change in Abdominal Symptom Scores at Week 24.

    Symptoms of myelofibrosis were assessed using a symptom diary, the modified MFSAF v2.0. Participants were issued a hand-held device to record answers to queries regarding 7 symptoms of myelofibrosis each night from Baseline through Week 24. The abdominal symptom score was the sum of 3 individual symptom scores (abdominal discomfort, pain under ribs on left side, and feeling of fullness \[early satiety\]).

    Time frame: Week 24

  12. Number of Participants With Grade 3 or Grade 4 Adverse Events

    Time frame: Baseline to the end of the study

Other outcomes

  1. Dose Distribution at Week 24

    Average Daily Dose for the last 28 days on study.

    Time frame: Week 24

07

Results

Posted Sep 19, 2014
Limitations and caveats
This was a single arm pilot study. The patient population differed from Phase III studies of ruxolitinib in myelofibrosis and therefore comparisons to standard dosing cannot be made from this study.

Participant flow

Participant flow — Overall Study
MilestoneRuxolitinib
Started45
Completed37
Not completed8
Withdrew: Consent withdrawn2
Withdrew: Disease progression1
Withdrew: Lost to follow-up5

Outcome measures

PrimaryMean Percentage Change From Baseline in Spleen Volume at Week 24

Spleen volume was measured using magnetic resonance imaging (MRI) or computed tomography (CT) scan. The MRIs were read in the central imaging laboratory. Spleen volume was obtained by outlining the circumference of the organ and determining the volume using the technique of least squares. MRI was the preferred method for obtaining spleen volume data. CT scans were performed if the participant was not a candidate for MRI. The CT scans were processed by the same central laboratory used for MRIs. The same method (MRI or CT) was used for all visits for a given participant unless a new contraindication to the use of MRI (eg, pacemaker insertion) occurred.

Time frame:
Baseline to Week 24
Reported as:
Mean · Percentage change
Mean Percentage Change From Baseline in Spleen Volume at Week 24
Percentage changeRuxolitinib
Mean Percentage Change From Baseline in Spleen Volume at Week 24-14.9 ± 21.06
PrimaryMedian Percent Change From Baseline in Spleen Volume at Week 24

Spleen volume was measured using magnetic resonance imaging (MRI) or computed tomography (CT) scan. The MRIs were read in the central imaging laboratory. Spleen volume was obtained by outlining the circumference of the organ and determining the volume using the technique of least squares. MRI was the preferred method for obtaining spleen volume data. CT scans were performed if the participant was not a candidate for MRI. The CT scans were processed by the same central laboratory used for MRIs. The same method (MRI or CT) was used for all visits for a given participant unless a new contraindication to the use of MRI (eg, pacemaker insertion) occurred.

Time frame:
Baseline to Week 24
Reported as:
Median · : Percentage change
Median Percent Change From Baseline in Spleen Volume at Week 24
: Percentage changeRuxolitinib
Median Percent Change From Baseline in Spleen Volume at Week 24-17.3 (-54.2 to 58.5)
SecondaryMean Percentage Change From Baseline in the Total Symptom Score at Week 24

Symptoms of myelofibrosis were assessed using a symptom diary, the modified Myelofibrosis Symptom Assessment Form (MFSAF v2.0). Participants were issued a hand-held device to record answers to queries regarding 7 symptoms of myelofibrosis each night from Baseline through Week 24. Symptoms assessed included night sweats, itching, abdominal discomfort, pain under ribs on left, feeling of fullness (early satiety), muscle/bone pain, and inactivity. The daily total symptom score (TSS) was the sum of the first 6 individual symptom scores (each on a scale of 0-10). Inactivity was not included in the total score. The Baseline TSS was the mean of daily total symptom scores from the last 7 consecutive days prior to the first study dose and ranged from 0 to 60. The Week 24 TSS was the mean of the daily total symptom scores from the last 28 consecutive days prior to the Week 24 visit and ranged from 0 to 60. A higher score indicates worse symptoms. A negative change score indicates improvement.

Time frame:
Baseline to Week 24
Reported as:
Mean · Percentage change
Mean Percentage Change From Baseline in the Total Symptom Score at Week 24
Percentage changeRuxolitinib
Mean Percentage Change From Baseline in the Total Symptom Score at Week 24-34.3 ± 69.05
SecondaryMedian Percent Change From Baseline in the Total Symptom Score at Week 24

Symptoms of myelofibrosis were assessed using a symptom diary, the modified MFSAF v2.0. Participants were issued a hand-held device to record answers to queries regarding 7 symptoms of myelofibrosis each night from Baseline through Week 24. Symptoms assessed included night sweats, itching, abdominal discomfort, pain under ribs on left, feeling of fullness (early satiety), muscle/bone pain, and inactivity. The daily TSS was the sum of the first 6 individual symptom scores (each on a scale of 0-10). Inactivity was not included in the total score. The Baseline total symptom score was the mean of daily total symptom scores from the last 7 consecutive days prior to the first study dose and ranged from 0 to 60. The Week 24 total symptom score was the mean of the daily total symptom scores from the last 28 consecutive days prior to the Week 24 visit and ranged from 0 to 60. A higher score indicates worse symptoms. A negative change score indicates improvement.

Time frame:
Baseline to Week 24
Reported as:
Median · Percentage change
Median Percent Change From Baseline in the Total Symptom Score at Week 24
Percentage changeRuxolitinib
Median Percent Change From Baseline in the Total Symptom Score at Week 24-45.6 (-100.0 to 261.9)
SecondaryPercentage of Participants With a ≥ 35% Reduction From Baseline in Spleen Volume at Week 24

Spleen volume was measured using magnetic resonance imaging (MRI) or computed tomography (CT) scan. The MRIs were read in the central imaging laboratory. Spleen volume was obtained by outlining the circumference of the organ and determining the volume using the technique of least squares. MRI was the preferred method for obtaining spleen volume data. CT scans were performed if the participant was not a candidate for MRI. The CT scans were processed by the same central laboratory used for MRIs. The same method (MRI or CT) was used for all visits for a given participant unless a new contraindication to the use of MRI (eg, pacemaker insertion) occurred.

Time frame:
Baseline to Week 24
Reported as:
Number · Percentage of participants
Percentage of Participants With a ≥ 35% Reduction From Baseline in Spleen Volume at Week 24
Percentage of participantsRuxolitinib
Percentage of Participants With a ≥ 35% Reduction From Baseline in Spleen Volume at Week 2415.6 (6.5 to 29.5)
SecondaryPercentage of Participants With a ≥ 10% Reduction From Baseline in Spleen Volume at Week 24

Spleen volume was measured using magnetic resonance imaging (MRI) or computed tomography (CT) scan. The MRIs were read in the central imaging laboratory. Spleen volume was obtained by outlining the circumference of the organ and determining the volume using the technique of least squares. MRI was the preferred method for obtaining spleen volume data. CT scans were performed if the participant was not a candidate for MRI. The CT scans were processed by the same central laboratory used for MRIs. The same method (MRI or CT) was used for all visits for a given participant unless a new contraindication to the use of MRI (eg, pacemaker insertion) occurred.

Time frame:
Baseline to Week 24
Reported as:
Number · Percentage of participants
Percentage of Participants With a ≥ 10% Reduction From Baseline in Spleen Volume at Week 24
Percentage of participantsRuxolitinib
Percentage of Participants With a ≥ 10% Reduction From Baseline in Spleen Volume at Week 2457.8 (42.2 to 72.3)
SecondaryPercentage of Participants With a ≥ 50% Improvement From Baseline in Total Symptom Score at Week 24

Symptoms of myelofibrosis were assessed using a symptom diary, the modified MFSAF v2.0. Participants were issued a hand-held device to record answers to queries regarding 7 symptoms of myelofibrosis each night from Baseline through Week 24. Symptoms assessed included night sweats, itching, abdominal discomfort, pain under ribs on left, feeling of fullness (early satiety), muscle/bone pain, and inactivity. The daily total symptom score was the sum of the first 6 individual symptom scores (each on a scale of 0-10). Inactivity was not included in the total score. The Baseline total symptom score was the mean of daily total symptom scores from the last 7 consecutive days prior to the first study dose and ranged from 0 to 60. The Week 24 total symptom score was the mean of the daily total symptom scores from the last 28 consecutive days prior to the Week 24 visit and ranged from 0 to 60. A higher score indicates worse symptoms. A negative change score indicates improvement.

Time frame:
Baseline to Week 24
Reported as:
Number · Percentage of participants
Percentage of Participants With a ≥ 50% Improvement From Baseline in Total Symptom Score at Week 24
Percentage of participantsRuxolitinib
Percentage of Participants With a ≥ 50% Improvement From Baseline in Total Symptom Score at Week 2440.0 (25.7 to 55.7)
SecondaryMean Percentage Change From Baseline in Palpable Spleen Length at Week 24

Spleen length was assessed by manual palpation. The edge of the spleen was determined by palpation and measured in centimeters, using a soft ruler, from the costal margin to the point of greatest splenic protrusion.

Time frame:
Baseline to Week 24
Reported as:
Mean · Percentage change
Mean Percentage Change From Baseline in Palpable Spleen Length at Week 24
Percentage changeRuxolitinib
Mean Percentage Change From Baseline in Palpable Spleen Length at Week 24-47.6 ± 42.05
SecondaryMedian Percent Change From Baseline in Palpable Spleen Length at Week 24

Spleen length was assessed by manual palpation. The edge of the spleen was determined by palpation and measured in centimeters, using a soft ruler, from the costal margin to the point of greatest splenic protrusion.

Time frame:
Baseline to Week 24
Reported as:
Median · Percentage change
Median Percent Change From Baseline in Palpable Spleen Length at Week 24
Percentage changeRuxolitinib
Median Percent Change From Baseline in Palpable Spleen Length at Week 24-39.8 (-100.0 to 26.7)
SecondaryPercentage of Participants With a ≥ 50% Improvement From Baseline in Their Transfusion Status or With New Transfusion Independence Status for Those Participants Who Were Transfusion Dependent at Baseline

Transfusion dependence at Baseline is defined as subjects who received ≥ 2 units of red blood cell product(s) in the 12 consecutive weeks prior to the date of first dose. Transfusion independence On-Study is defined as subjects who received 0 units of red blood cell products over any 12-week period after starting dosing with ruxolitinib. Improvement in transfusion dependence On-Study is defined as a 50% or greater reduction in the frequency of red blood cell transfusions over any 12-week period after starting dosing with ruxolitinib.

Time frame:
Baseline to Week 24
Reported as:
Number · Percentage of participants
Percentage of Participants With a ≥ 50% Improvement From Baseline in Their Transfusion Status or With New Transfusion Independence Status for Those Participants Who Were Transfusion Dependent at Baseline
Percentage of participantsRuxolitinib
Percentage of Participants With a ≥ 50% Improvement From Baseline in Their Transfusion Status or With New Transfusion Independence Status for Those Participants Who Were Transfusion Dependent at Baseline20.0 (4.3 to 48.1)
SecondaryPercentage of Participants With Clinically Notable Anemia

Clinically Notable Anemia was a pre-specified safety parameter examined at Weeks 12, 18 and 24 and defined as: 1) New onset Grade 3 or higher anemia in subjects who are transfusion independent at Baseline, 2) New onset transfusion dependence in subjects who are transfusion independent at Baseline, defined as receipt of ≥ 2 units in ≤ a 12-week interval, 3) 50% increase in transfusions compared to Baseline in subjects who are transfusion dependent at Baseline.

Time frame:
Baseline to Weeks 12, 18 and 24
Reported as:
Number · Percentage of participants
Percentage of Participants With Clinically Notable Anemia
Percentage of participantsRuxolitinib
Week 1233.3
Week 1827.3
Week 2427.9
SecondaryMean Percentage Change in Abdominal Symptom Scores at Week 24.

Symptoms of myelofibrosis were assessed using a symptom diary, the modified MFSAF v2.0. Participants were issued a hand-held device to record answers to queries regarding 7 symptoms of myelofibrosis each night from Baseline through Week 24. The abdominal symptom score was the sum of 3 individual symptom scores (abdominal discomfort, pain under ribs on left side, and feeling of fullness \[early satiety\]), each on a scale of 0 to 10. A higher score indicates worse symptoms. A negative change score indicates improvement. The Baseline abdominal symptom score was the mean of daily abdominal symptom scores from the last 7 consecutive days prior to the first study dose and ranged from 0 to 30. The Week 24 abdominal symptom score was the mean of the daily abdominal symptom scores from the last 28 consecutive days prior to the Week 24 visit and ranged from 0 to 30.

Time frame:
Week 24
Reported as:
Mean · Percentage change
Mean Percentage Change in Abdominal Symptom Scores at Week 24.
Percentage changeRuxolitinib
Mean Percentage Change in Abdominal Symptom Scores at Week 24.-33.2 ± 69.83
SecondaryMedian Percentage Change in Abdominal Symptom Scores at Week 24.

Symptoms of myelofibrosis were assessed using a symptom diary, the modified MFSAF v2.0. Participants were issued a hand-held device to record answers to queries regarding 7 symptoms of myelofibrosis each night from Baseline through Week 24. The abdominal symptom score was the sum of 3 individual symptom scores (abdominal discomfort, pain under ribs on left side, and feeling of fullness \[early satiety\]).

Time frame:
Week 24
Reported as:
Median · Percentage change
Median Percentage Change in Abdominal Symptom Scores at Week 24.
Percentage changeRuxolitinib
Median Percentage Change in Abdominal Symptom Scores at Week 24.-50.5 (-100.0 to 219.0)
SecondaryNumber of Participants With Grade 3 or Grade 4 Adverse Events
Time frame:
Baseline to the end of the study
Reported as:
Number · participants
Number of Participants With Grade 3 or Grade 4 Adverse Events
participantsRuxolitinib
Anemia (Grade 3)9
Thrombocytopenia (Grade 3)1
Umbilical hernia (Grade 3)1
Cholelithiasis (Grade 3)1
Blood creatine phosphokinase increased (Grade 3)1
Blood triglycerides increased (Grade 3)1
Lipase increased (Grade 3)1
Dehydration (Grade 3)1
Hyperkalaemia (Grade 3)1
Hypermagnesaemia (Grade 3)1
Dizziness (Grade 3)1
Myelodysplastic syndrome (Grade 4)1
Other pre-specifiedDose Distribution at Week 24

Average Daily Dose for the last 28 days on study.

Time frame:
Week 24
Reported as:
Number · participants
Dose Distribution at Week 24
participantsRuxolitinib
0-5 mg2
> 5-10 mg14
> 10-20 mg12
> 20-30 mg12
> 30-40 mg5

Adverse events

Collected over From the first dose of study medication through the Follow-Up Visit.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ruxolitinib—2/45 (4.4%)42/45 (93.3%)
Most frequent serious events
Most frequent serious events
EventRuxolitinib
CholelithiasisHepatobiliary disorders1/45
DehydrationMetabolism and nutrition disorders1/45
Most frequent other events
Showing 10 of 26
Most frequent other events
EventRuxolitinib
AnemiaBlood and lymphatic system disorders12/45
FatigueGeneral disorders10/45
ArthralgiaMusculoskeletal and connective tissue disorders9/45
ThrombocytopeniaBlood and lymphatic system disorders8/45
NauseaGastrointestinal disorders8/45
DizzinessNervous system disorders7/45
Abdominal painGastrointestinal disorders6/45
DiarrheaGastrointestinal disorders6/45
Oedema peripheralGeneral disorders6/45
Muscle spasmsMusculoskeletal and connective tissue disorders6/45

Baseline characteristics

Intent-to-treat population: All enrolled participants. Note that this was a pilot study which was not sufficiently powered.

Age, Continuous
Age, Continuous(years)Ruxolitinib
Mean70.2 ± 9.10
Sex: Female, Male
Sex: Female, Male(Participants)Ruxolitinib
Female21
Male24
08

Study locations

21 sites
  • Highland, California, United States
  • La Jolla, California, United States
  • Los Angeles, California, United States
  • Jacksonville, Florida, United States
  • Orange City, Florida, United States
  • Winter Park, Florida, United States
  • Atlanta, Georgia, United States
  • Augusta, Georgia, United States
  • Iowa City, Iowa, United States
  • Baltimore, Maryland, United States
  • Ann Arbor, Michigan, United States
  • Southfield, Michigan, United States
  • Morristown, New Jersey, United States
  • Armonk, New York, United States
  • Hickory, North Carolina, United States
  • Canton, Ohio, United States
  • Hazleton, Pennsylvania, United States
  • Hershey, Pennsylvania, United States
  • Charleston, South Carolina, United States
  • Sioux Falls, South Dakota, United States
  • San Antonio, Texas, United States
09

References and documents

Publications

  • Talpaz M, Erickson-Viitanen S, Hou K, Hamburg S, Baer MR. Evaluation of an alternative ruxolitinib dosing regimen in patients with myelofibrosis: an open-label phase 2 study. J Hematol Oncol. 2018 Aug 7;11(1):101. doi: 10.1186/s13045-018-0642-0. PubMed 30086777 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2011, a primary completion of Mar 2013 and a completion of Apr 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2014, 1 year 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 23, 2011
First posted
Oct 4, 2011
Start
Sep 2011
Primary completionActual
Mar 2013
CompletionActual
Apr 2013
Results first posted
Sep 19, 2014
Last update
Mar 27, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 27, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01445769
Lead sponsor
Incyte Corporation
Responsible party
Sponsor
First posted
Oct 4, 2011
Start date
Sep 2011
Primary completion
Mar 2013
Completion
Apr 2013
Results posted
Sep 19, 2014
Last update
Mar 27, 2019

Study contacts

William V Williams, MD
study director · Incyte Corporation

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ruxolitinib

Start the discussion